What is the PMN.TO share price today?

This page shows the latest available ProMIS Neurosciences, Inc. (PMN.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is ProMIS Neurosciences, Inc. listed?

ProMIS Neurosciences, Inc. trades on the Toronto Stock Exchange under the symbol PMN.TO, ISIN CA74346M1095.

How large is ProMIS Neurosciences, Inc.?

Its market capitalisation is approximately 51.48M CAD, based on the latest available price and share count from our data provider.

Toronto Stock Exchange (TSX) · PMN.TO · ISIN CA74346M1095

ProMIS Neurosciences, Inc.

No trading activity has been reported for this listing since July 21, 2023. It may be delisted, halted or inactive.

6.00 CAD

July 21, 2023

ProMIS Neurosciences, Inc. (PMN.TO) trades on the Toronto Stock Exchange and operates in the Biotechnology industry. Its market capitalisation is approximately 51.48M CAD. The company reports around 6 employees. Its ISIN is CA74346M1095. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Key facts

Exchange

Toronto Stock Exchange (TSX)

ISIN

CA74346M1095

Sector

Healthcare

Industry

Biotechnology

Country

Market cap

51.48M CAD

Employees

Previous close

6.24 CAD

Day range

5.98 – 6.49

52-week range

3.34 – 11.10

Volume

19.7K

50-day average

6.16 CAD

200-day average

6.95 CAD

Asset type

Equity

About ProMIS Neurosciences, Inc.

Based in Toronto, Canada, ProMIS Neurosciences, Inc. focuses on developing precise medical solutions for severe neurodegenerative disorders, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company employs a unique discovery platform, which incorporates proprietary algorithms like ProMIS and Collective Coordinates, to identify novel, disease-specific targets, known as epitopes, located on the surface of misfolded proteins. The firm's primary product candidates include PMN310, a monoclonal antibody designed to combat toxic oligomers associated with Alzheimer's disease. Another candidate, PMN267, aims to target proteins such as superoxide dismutase 1 and TAR-DNA binding protein 43 relevant to ALS, as well as alpha-synuclein implicated in Parkinson's disease and Lewy body dementia. Additionally, PMN442 is a monoclonal antibody engineered to address toxic alpha-synuclein oligomers and seeding fibrils linked to MSA. Originally established in 2004, the company was known as Amorfix Life Sciences Ltd. before officially adopting the name ProMIS Neurosciences, Inc. in July 2015.

Company website

Frequently asked

What is the PMN.TO share price today?: This page shows the latest available ProMIS Neurosciences, Inc. (PMN.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is ProMIS Neurosciences, Inc. listed?: ProMIS Neurosciences, Inc. trades on the Toronto Stock Exchange under the symbol PMN.TO, ISIN CA74346M1095.
How large is ProMIS Neurosciences, Inc.?: Its market capitalisation is approximately 51.48M CAD, based on the latest available price and share count from our data provider.

All ProMIS Neurosciences, Inc. data comes from exchange and provider feeds for the Toronto Stock Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.